+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Arthropod-borne Viral Infections Testing Market by Test Type, Technology, End User, Sample Type, Disease Type - Global Forecast to 2030- Product Image
Arthropod-borne Viral Infections Testing Market by Test Type, Technology, End User, Sample Type, Disease Type - Global Forecast to 2030- Product Image
Sale

Arthropod-borne Viral Infections Testing Market by Test Type, Technology, End User, Sample Type, Disease Type - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5336731
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The arthropod-borne viral infections testing market is evolving rapidly as public health authorities, hospitals, and laboratories seek effective solutions to address rising global viral threats. Stakeholders are prioritizing innovative technologies and partnerships to drive operational efficiency, resilience, and responsiveness in disease detection frameworks.

Market Snapshot: Arthropod-Borne Viral Infections Testing

The arthropod-borne viral infections testing market grew from USD 12.18 billion in 2024 to USD 13.52 billion in 2025. It is expected to continue growing at a CAGR of 10.91%, reaching USD 22.68 billion by 2030. This momentum is fueled by mounting clinical demand for early detection, improved assay sensitivity, and faster workflows as emerging and re-emerging pathogens strain healthcare infrastructure across all major regions.

Scope & Segmentation

  • Test Types: Antibody Testing (including IgG Antibody, IgM Antibody), Antigen Testing (Elisa Antigen, Rapid Antigen), and Molecular Testing (Conventional PCR, Isothermal Amplification, Real Time PCR).
  • Technologies: Immunoassay (Chemiluminescent Immunoassay, Elisa, Lateral Flow Immunoassay), Next Generation Sequencing (Illumina, Pyrosequencing), PCR-Based Technologies (Conventional PCR, Isothermal Amplification, Real Time PCR), Rapid Diagnostic Tests (Lateral Flow Assay, Optical Immunoassay).
  • End Users: Academic Institutions, Diagnostic Centers, Hospital Laboratories, Reference Laboratories, Research Institutes.
  • Sample Types: Blood Serum, Cerebrospinal Fluid, Plasma, Saliva, Whole Blood.
  • Disease Types: Chikungunya, Dengue, West Nile, Yellow Fever, Zika.
  • Geographies: Americas (United States regions, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (key markets including UK, Germany, France, and others), Asia-Pacific (China, India, Japan, and additional growth markets).
  • Leading Companies: F. Hoffmann-La Roche Ltd., Abbott Laboratories, Thermo Fisher Scientific Inc., QIAGEN N.V., bioMérieux SA, DiaSorin S.p.A., Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Siemens Healthineers AG, Luminex Corporation.

Key Takeaways: Strategic Insights for Decision-Makers

  • Integration of molecular and traditional serological assays is transforming diagnostic workflows, enabling faster and more reliable detection across a broader pathogen spectrum.
  • Adoption of high-throughput and portable rapid diagnostic solutions supports both centralized and point-of-care testing, expanding operational reach into emerging and underserved regions.
  • Automation, digital reporting, and data integration are optimizing laboratory performance, enabling real-time surveillance and informed decision-making for public health stakeholders.
  • Strategic partnerships among diagnostic leaders, academia, and contract research organizations are accelerating product validation, regulatory alignment, and local manufacturing initiatives.
  • Market demand is shaped by disease-specific needs, versatile sample types, and regional outbreaks, prompting tailored assay innovation and investments in localized diagnostics infrastructure.

Tariff Impact: Shifting Supply Chains and Cost Strategies

Revised United States tariff policies on imported diagnostic reagents and assay components are reshaping supply chain strategies and cost structures. Laboratories sourcing molecular reagents from abroad face higher input expenses, triggering margin pressures and prompting some suppliers to expand regional production. Manufacturers are innovating reagent formulation, exploring modular kits, and optimizing packaging to mitigate cost volatility and support long-term supply chain resilience.

Methodology & Data Sources

This research employs a rigorous mixed-methodology framework, combining interviews with industry opinion leaders, laboratory directors, and procurement experts with secondary review of regulatory filings, scientific literature, and company announcements. Robust data triangulation, regional field studies, and validation workshops with subject matter experts ensure the accuracy and relevance of all findings for your strategic planning needs.

Why This Report Matters

  • Enable strategic investment and procurement by leveraging deep insight into evolving technologies, competitive landscapes, and regional trends.
  • Inform portfolio development, supply chain planning, and risk mitigation through actionable segmentation and regulatory context.
  • Enhance decision-making confidence with a transparent, quality-assured assessment aligned to operational realities and stakeholder priorities.

Conclusion

The arthropod-borne viral infections testing market is poised for ongoing transformation, driven by collaboration, technological advancements, and an expanding need for rapid, high-accuracy diagnostics. Proactive engagement with shifting regulations and localized supply strategies will position stakeholders for resilience and growth within this dynamic environment.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Arthropod-borne Viral Infections Testing Market, by Test Type
8.1. Introduction
8.2. Antibody Testing
8.2.1. IgG Antibody
8.2.2. IgM Antibody
8.3. Antigen Testing
8.3.1. Elisa Antigen
8.3.2. Rapid Antigen
8.4. Molecular Testing
8.4.1. Conventional PCR
8.4.2. Isothermal Amplification
8.4.3. Real Time PCR
9. Arthropod-borne Viral Infections Testing Market, by Technology
9.1. Introduction
9.2. Immunoassay
9.2.1. Chemiluminescent Immunoassay
9.2.2. Elisa
9.2.3. Lateral Flow Immunoassay
9.3. Next Generation Sequencing
9.3.1. Illumina Sequencing
9.3.2. Pyrosequencing
9.4. PCR Based Technologies
9.4.1. Conventional PCR
9.4.2. Isothermal Amplification
9.4.3. Real Time PCR
9.5. Rapid Diagnostic Test
9.5.1. Lateral Flow Assay
9.5.2. Optical Immunoassay
10. Arthropod-borne Viral Infections Testing Market, by End User
10.1. Introduction
10.2. Academic Institutions
10.3. Diagnostic Centers
10.4. Hospital Laboratories
10.5. Reference Laboratories
10.6. Research Institutes
11. Arthropod-borne Viral Infections Testing Market, by Sample Type
11.1. Introduction
11.2. Blood Serum
11.3. Cerebrospinal Fluid
11.4. Plasma
11.5. Saliva
11.6. Whole Blood
12. Arthropod-borne Viral Infections Testing Market, by Disease Type
12.1. Introduction
12.2. Chikungunya
12.3. Dengue
12.4. West Nile
12.5. Yellow Fever
12.6. Zika
13. Americas Arthropod-borne Viral Infections Testing Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Arthropod-borne Viral Infections Testing Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Arthropod-borne Viral Infections Testing Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd.
16.3.2. Abbott Laboratories
16.3.3. Thermo Fisher Scientific Inc.
16.3.4. QIAGEN N.V.
16.3.5. bioMérieux SA
16.3.6. DiaSorin S.p.A.
16.3.7. Bio-Rad Laboratories, Inc.
16.3.8. Becton, Dickinson and Company
16.3.9. Siemens Healthineers AG
16.3.10. Luminex Corporation
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET MULTI-CURRENCY
FIGURE 2. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET MULTI-LANGUAGE
FIGURE 3. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGG ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IGM ANTIBODY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA ANTIGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID ANTIGEN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PYROSEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CONVENTIONAL PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REAL TIME PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY LATERAL FLOW ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY OPTICAL IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY BLOOD SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CEREBROSPINAL FLUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY CHIKUNGUNYA, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DENGUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY WEST NILE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ZIKA, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 83. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 84. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 85. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 86. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 87. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 88. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 89. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 90. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 91. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 92. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 94. CANADA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 95. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 97. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 98. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 99. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 100. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 102. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 103. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 104. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 105. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 106. MEXICO ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 119. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 120. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 121. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 122. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 123. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 124. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 144. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 146. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 156. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 157. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 158. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 159. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 160. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 161. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 162. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 163. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 164. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 165. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 167. GERMANY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 168. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 169. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 170. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 171. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 172. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 173. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 174. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 175. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 176. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 177. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 178. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 179. FRANCE ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 180. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 181. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 182. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 183. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 184. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 186. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 187. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 188. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 192. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 193. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 194. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 195. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 196. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 197. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 198. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 199. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 200. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 201. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 203. ITALY ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 204. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 205. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 206. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 207. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 208. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 209. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 210. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 211. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 212. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 213. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 215. SPAIN ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 228. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 246. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 248. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 249. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 250. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 251. SOUTH AFRICA ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 252. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 253. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 254. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 255. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 256. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 257. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 258. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 259. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 260. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 261. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 262. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 263. DENMARK ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 264. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 265. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIBODY TESTING, 2018-2030 (USD MILLION)
TABLE 266. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY ANTIGEN TESTING, 2018-2030 (USD MILLION)
TABLE 267. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY MOLECULAR TESTING, 2018-2030 (USD MILLION)
TABLE 268. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 269. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 270. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 271. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY PCR BASED TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 272. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2030 (USD MILLION)
TABLE 273. NETHERLANDS ARTHROPOD-BORNE VIRAL INFECTIONS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 274. NETHERLANDS ARTHROPOD-BORNE VIRA

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Arthropod-borne Viral Infections Testing market report include:
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Thermo Fisher Scientific Inc.
  • QIAGEN N.V.
  • bioMérieux SA
  • DiaSorin S.p.A.
  • Bio-Rad Laboratories, Inc.
  • Becton, Dickinson and Company
  • Siemens Healthineers AG
  • Luminex Corporation

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 13.52 Billion
Forecasted Market Value ( USD ) by 2030 $ 22.68 Billion
Compound Annual Growth Rate10.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Arthropod-Borne Viral Infection Testing Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Arthropod-Borne Viral Infection Testing Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Peters' Atlas of Tropical Medicine and Parasitology. Edition No. 7 - Product Image

Peters' Atlas of Tropical Medicine and Parasitology. Edition No. 7

  • Book
Hunter's Tropical Medicine and Emerging Infectious Diseases. Edition No. 10 - Product Image

Hunter's Tropical Medicine and Emerging Infectious Diseases. Edition No. 10

  • Book
Modernizing Global Health Security to Prevent, Detect, and Respond - Product Image

Modernizing Global Health Security to Prevent, Detect, and Respond

  • Book
  • Global
Ectoparasitic Diseases - Product Image

Ectoparasitic Diseases

  • Book
Copyright © 2002-2025 Research and Markets. All Rights Reserved.